How TransCelerate’s clinical data sharing platforms are improving clinical development
TransCelerate BioPharma Inc. is taking its data sharing initiative to the next level with a new platform that will integrate clinical and preclinical data sets in a single repository and provide new analytical tools. DataCelerate, a data-sharing platform launched in July, will initially provide insights into the causes of toxicological findings.
The platform currently contains in vivo preclinical toxicology data. Once TransCelerate migrates its clinical data into the new platform, companies should be able to use the combined data to improve the predictive power of their preclinical studies.
TransCelerate is a precompetitive consortium of 19 companies working on multiple initiatives to resolve clinical trial bottlenecks. In 2015, it announced the Placebo and Standard of Care Data (PSoC) Sharing initiative to collect and share de-identified patient-level data from the control arms of clinical trials conducted by the consortium’s members. The PSoC repository now contains data from placebo and control arms from more than 130 clinical studies spanning nearly 20 therapeutic areas. Data are available only to member companies that commit to contributing data.
TransCelerate said in an emailed statement to BioCentury that 15 of the group’s member